Figure 1.
CONSORT flow diagram.
Table 1.
Baseline demographic and anthropometric characteristics.
Table 2.
Comparison of reported average (28 days) intake of protein, sodium, and potassium with the corresponding biological markers in urine in the caloric restriction (CR) diet group.
Figure 2.
Median plasma concentrations of F2-isoprostane (prostaglandin F2-like compound) in overweight and obese women at baseline (Day 0), during dietary intervention (Days 1–29), and after 90-day follow-up (Days 42 and 119) in the CR (caloric restricted) diet (75% of energy requirement) group (n = 32) and in the control group (n = 8) without diet restrictions (100% of energy requirement).
Vertical bars represent 95% bootstrap confidence intervals.
Table 3.
Multivariable linear regression results for change in F2-isoprostane serum levels during the 28-day dietary intervention.
Table 4.
Differences in F2-isoprostane (pg/mL) serum levels between caloric restriction (CR) and control groups at baseline (Day 0), during the intervention (Days 1 to 29), and follow-up (Days 42 and 119).
Table 5.
Body weight, BMI, and body fat mass at baseline, end of intervention (Day 29), and follow-up (Day 119).
Table 6.
Resting energy expenditure, physical activity-related energy expenditure and physical activity level (PAL) at baseline, end of intervention (Day 29), and day follow-up (Day 119).
Table 7.
Median daily macro- and selected micro-nutrient intake in the caloric restriction (CR) and Control diet groups.
Table 8.
Blood pressure, hormones, and lipids at baseline, end of intervention (Day 29), and follow-up (Day 119).
Table 9.
Inflammatory markers at baseline, end of intervention (Day 29), and follow-up (Day 119).